-
1Academic Journal
Source: Клиническая онкогематология, Vol 17, Iss 3 (2024)
-
2Academic Journal
Authors: A. M. Lila, A. L. Maslyanskiy, D. A. Dibrov, A. V. Torgashina, E. G. Zotkin, M. Yu. Samsonov, А. М. Лила, А. Л. Маслянский, Д. А. Дибров, А. В. Торгашина, Е. Г. Зоткин, М. Ю. Самсонов
Contributors: The work was performed as a part of the basic scientific topic 125020501434-1, Работа выполнена в рамках фундаментальной темы 125020501434-1
Source: Modern Rheumatology Journal; Том 19, № 2 (2025); 7-17 ; Современная ревматология; Том 19, № 2 (2025); 7-17 ; 2310-158X ; 1996-7012
Subject Terms: моноклональные антитела, depletion-restitution therapy, B-cells, plasma cells, bispecific antibodies, monoclonal antibodies, деплеционно-реституционная терапия, В-клетки, плазматические клетки, биспецифические антитела
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1734/1578; Насонов ЕЛ. Перспективы анти-В-клеточной терапии в ревматологии. Научно-практическая ревматология 2018;56(5): 539-548.; Pouw JN, Leijten EFA, van Laar JM, Boes M. Revisiting B cell tolerance and autoantibodies in seropositive and seronegative autoimmune rheumatic disease (AIRD). Clin Exp Immunol. 2021 Feb;203(2):160-173. doi:10.1111/cei.13542. Epub 2020 Nov 15.; Maschmeyer P, Chang HD, Cheng Q, et al. Immunological memory in rheumatic inflammation – a roadblock to tolerance induction. Nat Rev Rheumatol. 2021 May;17(5):291-305. doi:10.1038/s41584-021-00601-6. Epub 2021 Apr 6.; Khader Y, Beran A, Ghazaleh S, et al. Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis. Clin Rheumatol. 2022 Dec;41(12):3615-3627. doi:10.1007/s10067-022-06307-8. Epub 2022 Aug 16.; Ugarte-Gil MF, Mendoza-Pinto C, Reategui-Sokolova C, et al. Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. Lupus Sci Med. 2021 Sep;8(1):e000542. doi:10.1136/lupus-2021-000542.; Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016 Jan;75(1):3-15. doi:10.1136/annrheumdis-2015-207524. Epub 2015 May 12.; Konzett V, Aletaha D. Management strategies in rheumatoid arthritis. Nat Rev Rheumatol. 2024 Dec;20(12):760-769. doi:10.1038/s41584-024-01169-7. Epub 2024 Oct 24.; Riley TR, George MD. Risk for infections with glucocorticoids and DMARDs in pati ents with rheumatoid arthritis. RMD Open. 2021 Feb;7(1):e001235. doi:10.1136/rmdopen-2020-001235.; Nguyen Y, Costedoat-Chalumeau N. Serious infections in patients with systemic lupus erythematosus: how can we prevent them? Lancet Rheumatol. 2023 May;5(5):e245-e246. doi:10.1016/S2665-9913(23)00096-6.; Ramirez-Valle F, Maranville JC, Roy S, Plenge RM. Sequential immunotherapy: towards cures for autoimmunity. Nat Rev Drug Discov. 2024 Jul;23(7):501-524. doi:10.1038/s41573-024-00959-8. Epub 2024 Jun 5.; Alexander T, Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2022 Jul;57(7):1055-1062. doi:10.1038/s41409-022-01702-w. Epub 2022 May 16.; Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023 Nov 25;402(10416):2034-2044. doi:10.1016/S0140-6736(23)01126-1. Epub 2023 Sep 22.; Sorensen PS, Sellebjerg F. Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord. 2019 Mar 28:12: 1756286419836913. doi:10.1177/1756286419836913. e Collection 2019.; Hecker M, Fitzner B, Boxberger N, et al. Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy. J Neuroinflammation. 2023 Aug 2;20(1):181. doi:10.1186/s12974-023-02859-x.; Muthu S, Jeyaraman M, Ranjan R, Jha SK. Remission is not maintained over 2 years with hematopoietic stem cell transplantation for rheumatoid arthritis: A systematic review with meta-analysis. World J Biol Chem. 2021 Nov 27;12(6):114-130. doi:10.4331/wjbc.v12.i6.114.; Bagnato G, Versace AG, La Rosa D, et al. Autologous Haematopoietic Stem Cell Transplantation and Systemic Sclerosis: Focus on Interstitial Lung Disease. Cells. 2022 Mar 1; 11(5):843. doi:10.3390/cells11050843.; Насонов ЕЛ, Румянцев АГ, Самсонов МЮ. Фармакотерапия аутоиммунных ревматических заболеваний – от моноклональных антител к CAR-T-клеткам: 20 лет спустя. Научно-практическая ревматология 2024;62(3):262-279.; Маслянский АЛ, Мазуров ВИ, Зоткин ЕГ и др. Анти-В-клеточная терапия аутоиммунных заболеваний. Медицинская иммунология. 2007;9(1):15-34.; Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007 Jun 5;146(11):797-808. doi:10.7326/0003-4819-146-11-200706050-00008.; Маслянский АЛ, Лапин СВ, Мазинг АВ и др. Диагностическая значимость серологических маркеров ревматоидного артрита. Научно-практическая ревматология. 2012;50(5):20-24.; Насонов ЕЛ. Проблемы иммунопатологии ревматоидного артрита: эволюция болезни. Научно-практическая ревматология. 2017;55(3):277-294.; Kerkman PF, Fabre E, van der Voort EI, et al. Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Jun;75(6): 1170-6. doi:10.1136/annrheumdis-2014-207182. Epub 2015 Jun 1.; Kerkman PF, Rombouts Y, van der Voort EI, et al. Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. Ann Rheum Dis. 2013 Jul;72(7):1259-63. doi:10.1136/annrheumdis-2012-202893. Epub 2013 Apr 26.; Humby F, Bombardieri M, Manzo A, et al. Ectopic lymphoid structures support on-going production of class-switched autoantibodies in rheumatoid synovium. PLoS Med. 2009 Jan 13;6(1):e1. doi:10.1371/journal.pmed.0060001.; Corsiero E, Bombardieri M, Carlotti E, et al. Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs. Ann Rheum Dis. 2016 Oct;75(10):1866-75. doi:10.1136/annrheumdis-2015-208356. Epub 2015 Dec 9.; Kerkman PF, Kempers AC, van der Voort EI, et al. Synovial fluid mononuclear cells provide an environment for long-term survival of antibody-secreting cells and promote the spontaneous production of anti-citrullinated protein antibodies. Ann Rheum Dis. 2016 Dec;75(12): 2201-2207. doi:10.1136/annrheumdis-2015-208554. Epub 2016 Apr 11.; Volkov M, van Schie KA, van der Woude D. Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology. Immunol Rev. 2020 Mar;294(1):148-163. doi:10.1111/imr.12829. Epub 2019 Dec 16.; Steffen U, Schett G, Bozec A. How Autoantibodies Regulate Osteoclast Induced Bone Loss in Rheumatoid Arthritis. Front Immunol. 2019 Jul 3:10:1483. doi:10.3389/fimmu.2019.01483 .e Collection 2019.; Nie Y, Zhao L, Zhang X. B Cell Aberrance in Lupus: the Ringleader and the Solution. Clin Rev Allergy Immunol. 2022 Apr;62(2): 301-323. doi:10.1007/s12016-020-08820-7. Epub 2021 Feb 3.; Yung S, Chan TM. Mechanisms of Kidney Injury in Lupus Nephritis – the Role of AntidsDNA Antibodies. Front Immunol. 2015 Sep 15:6:475. doi:10.3389/fimmu.2015.00475. e Collection 2015.; Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus. Lupus Sci Med. 2015 Mar 3;2(1):e000078. doi:10.1136/lupus-2014-000078. E Collection 2015.; Насонов ЕЛ, Решетняк ТМ, Соловь ев СК, Попкова ТВ. Системная красная волчанка и антифосфолипидный синдром: вчера, сегодня, завтра. Терапевтический архив 2023;95(5):367-374.; Lovgren T, Eloranta ML, Kastner B, et al. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum. 2006 Jun;54(6):1917-27. doi:10.1002/art.21893.; Melissaropoulos K, Iliopoulos G, Sakkas LI, Daoussis D. Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells. Front Immunol. 2022 Jun 23:13:925741. doi:10.3389/fimmu.2022.925741. e Collection 2022.; Fleischmajer R, Perlish JS, Reeves JR. Cellular infiltrates in scleroderma skin. Arthritis Rheum. 1977 May;20(4):975-84. doi:10.1002/art.1780200410.; Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum. 2007 Sep;56(9):3167-8. doi:10.1002/art.22847.; Roumm AD, Whiteside TL, Meds ger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 1984 Jun;27(6): 645-53. doi:10.1002/art.1780270607.; De Santis M, Bosello SL, Peluso G, et al. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. Clin Respir J. 2012 Jan;6(1):9-17. doi:10.1111/j.1752-699X.2010.00228.x. Epub 2010 Nov 25.; Sato S, Hasegawa M, Fujimoto M, et alK. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol. 2000 Dec 1;165(11):6635-43. doi:10.4049/jimmunol.165.11.6635.; Лазарева НМ, Лапин СВ, Мазинг АВ, et al. Оптимизация комплекса серологических методов диагностики системных заболеваний соединительной ткани. Клиническая лабораторная диагностика. 2011; (12):12-17.; Dumoitier N, Chaigne B, Regent A, et al. Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor beta and Activate Fibroblasts. Arthritis Rheumatol. 2017 May;69(5):1078-1089. doi:10.1002/art.40016.; Francois A, Chatelus E, Wachsmann D, et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther. 2013 Oct 28;15(5): R168. doi:10.1186/ar4352.; Numajiri H, Kuzumi A, Fukasawa T, et al. B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis. Arthritis Rheumatol. 2021 Nov;73(11): 2086-2095. doi:10.1002/art.41798. Epub 2021 Sep 28.; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2020.; Fassbinder T, Saunders U, Mickholz E, et al. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. Arthritis Res Ther. 2015 Apr 3;17(1):92. doi:10.1186/s13075-015-0603-8.; Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int. 2011 Nov;31(11): 1493-9. doi:10.1007/s00296-010-1526-y. Epub 2010 May 16.; Habibi MA, Alesaeidi S, Zahedi M, et al. The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review. Biology (Basel). 2022 Dec 6;11(12): 1767. doi:10.3390/biology11121767.; Kaegi C, Wuest B, Schreiner J, et al. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front Immunol. 2019 Sep 6:10: 1990. doi:10.3389/fimmu.2019.01990. e Collection 2019.; Isaacs JD, Cohen SB, Emery P, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis. 2013 Mar;72(3):329-36. doi:10.1136/annrheumdis-2011-201117. Epub 2012 Jun 11.; Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituxi mab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European regist ries. Ann Rheum Dis. 2011 Sep;70(9):1575-80. doi:10.1136/ard.2010.148759. Epub 2011 May 12.; Pugliesi A, de Oliveira AB, Oliveira AB, et al. Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexa te or TNF inhibitors agents: a systematic review and network meta-analysis. Adv Rheumatol. 2023 Jul 6;63(1):30. doi:10.1186/s42358-023-00298-z.; Авдеева АС, Сатыбалдыев АМ, Демидова НВ и др. Оценка терапии ритуксимабом в реальной клинической практике (по данным регистра больных ревматоидным артритом ОРЕЛ). Научно-практическая ревматология 2019;57(3):274-279.; De Keyser F, Hoffman I, Durez P, et al. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry. J Rheumatol. 2014 Sep; 41(9):1761-5. doi:10.3899/jrheum.131279. Epub 2014 Aug 15.; Harrold LR, Reed GW, Shewade A, et al. Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry. J Rheumatol. 2015 Jul;42(7):1090-8. doi:10.3899/jrheum.141043. Epub 2015 May 1.; Wendler J, Burmester GR, Sorensen H, et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 pati ents. Arthritis Res Ther. 2014 Mar 26;16(2): R80. doi:10.1186/ar4521.; Shah K, Cragg M, Leandro M, Reddy V. Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus. Biologicals. 2021 Jan:69:1-14. doi:10.1016/j.biologicals.2020.11.002. Epub 2020 Dec 4.; Roveta A, Parodi EL, Brezzi B, et al. Lupus Nephritis from Pathogenesis to New Therapies: An Update. Int J Mol Sci. 2024 Aug 18;25(16):8981. doi:10.3390/ijms25168981.; Tanaka Y, Nakayamada S, Yamaoka K, et al. Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan. Mod Rheumatol. 2023 Jan 3;33(1): 145-153. doi:10.1093/mr/roac007.; Li K, Yu Y, Gao Y, et al. Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systema tic Review and Network Meta-Analysis. Front Immunol. 2022 Apr 4:13:859380. doi:10.3389/fimmu.2022.859380. e Collection 2022.; Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 Apr;64(4):1215-26. doi:10.1002/art.34359. Epub 2012 Jan 9.; Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in mode rately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan;62(1):222-33. doi:10.1002/art.27233.; Гарзанова ЛА. Ритуксимаб в лечении системной склеродермии. Научно-практическая ревматология 2023;61(4):466-474.; Goswami RP, Ray A, Chatterjee M, et al. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology (Oxford). 2021 Feb 1;60(2):557-567. doi:10.1093/rheumatology/keaa550.; Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, doubledummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023 Jan;11(1):45-54. doi:10.1016/S2213-2600(22)00359-9. Epub 2022 Nov 11.; Lindenberg L, Spengler L, Bang H, et al. Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis. Arthritis Res Ther. 2015 Aug 13; 17(1):206. doi:10.1186/s13075-015-0717-z.; Pirone C, Mendoza-Pinto C, van der Windt DA, et al. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review. Semin Arthritis Rheum. 2017 Dec;47(3):384-396. doi:10.1016/j.semarthrit.2017.04.010. Epub 2017 May 5.; Youkhana K, Heiling H, Deal A, Moll S. The Effect of Rituximab on Antiphospholipid Titers in Patients with Antiphospholipid Syndrome. TH Open. 2023 Jul 5;7(3):e191-e194. doi:10.1055/s-0043-1770784. E Collection 2023 Jul.; Tomita A. Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. J Clin Exp Hematop. 2016;56(2):89-99. doi:10.3960/jslrt.56.89.; Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemo therapies: its prevalence and clinical significance. Blood. 2009 May 14;113(20):4885-93. doi:10.1182/blood-2008-08-175208. Epub 2009 Feb 26.; Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, et al. Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology (Oxford). 2019 Jun 1;58(6):1075-1085. doi:10.1093/rheumatology/key428.; Kamburova EG, Koenen HJ, Borgman KJ, et al. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant. 2013 Jun;13(6):1503-11. doi:10.1111/ajt.12220. Epub 2013 Apr 9.; Rehnberg M, Amu S, Tarkowski A, et al. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123. doi:10.1186/ar2789. Epub 2009 Aug 17.; Teng YK, Levarht EW, Toes RE, et al. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis. 2009 Jun;68(6): 1011-6. doi:10.1136/ard.2008.092791. Epub 2008 Jul 22.; Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008 Jul;67(7):917-25. doi:10.1136/ard.2007.080960. Epub 2007 Oct 26.; Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004 Mar 1;172(5):3280-8. doi:10.4049/jimmunol.172.5.3280.; Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complementmediated cell lysis. Blood. 2000 Jun 15; 95(12):3900-8.; Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022 Jan;81(1):100-107. doi:10.1136/annrheumdis-2021-220920. Epub 2021 Oct 6; Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010 Jun 3;115(22):4393-402. doi:10.1182/blood-2009-06-225979. Epub 2010 Mar 1.; Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. Adv Ther. 2017 Feb;34(2):324-356. doi:10.1007/s12325-016-0451-1. Epub 2016 Dec 21.; Rubin SJS, Bloom MS, Robinson WH. B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol. 2019 May;15(5): 303-315. doi:10.1038/s41584-019-0211-0.; Wingerchuk DM, Lennon VA, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 May 23;66(10):1485-9. doi:10.1212/01.wnl.0000216139.44259.74.; Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuro myelitis optica spectrum disorder (N-MO-mentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Oct 12;394(10206):1352-1363. doi:10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5.; Flanagan EP, Levy M, Katz E, et al. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Mult Scler Relat Disord. 2022 Jan:57:103352. doi:10.1016/j.msard.2021.103352. Epub 2021 Oct 26.; Schiopu E, Chatterjee S, Hsu V, et al. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016 Jun 7;18(1): 131. doi:10.1186/s13075-016-1021-2.; Stone JH, Khosroshahi A, Zhang W, et al. Inebilizumab for Treatment of IgG4-Related Disease. N Engl J Med. 2024 Nov 14. doi:10.1056/NEJMoa2409712. Online ahead of print.; Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008 Jul;88(3):841-86. doi:10.1152/physrev.00035.2007.; Wardowska A, Komorniczak M, Skoniecka A, et al. Alterations in peripheral blood B cells in systemic lupus erythematosus patients with renal insufficiency. Int Immunopharmacol. 2020 Jun:83:106451. doi:10.1016/j.intimp.2020.106451. Epub 2020 Apr 2.; Lugar PL, Love C, Grammer AC, et al. Molecular characterization of circulating plasma cells in patients with active systemic lupus erythematosus. PLoS One. 2012;7(9): e44362. doi:10.1371/journal.pone.0044362. Epub 2012 Sep 21.; Cole S, Walsh A, Yin X, et al. Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2018 May 2; 20(1):85. doi:10.1186/s13075-018-1578-z.; Chang X, Yue L, Liu W, et al. CD38 and E2F transcription factor 2 have uniquely increased expression in rheumatoid arthritis synovial tissues. Clin Exp Immunol. 2014 May; 176(2):222-31. doi:10.1111/cei.12268.; Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016 Jun 30;9(1):51. doi:10.1186/s13045-016-0283-0.; Alexander T, Ostendorf L, Zernicke J, et al. LBA0007 Safety and efficacy of daratumumab in systemic lupus erythematosus – a single-center phase 2 open-label trial. Ann Rheum Dis. 2024;83(Suppl 1):237-238. doi:10.1136/annrheumdis-2024-eular.LBA26.; Roccatello D, Fenoglio R, Caniggia I, et al. Daratumumab monotherapy for refractory lupus nephritis. Nat Med. 2023 Aug;29(8): 2041-2047. doi:10.1038/s41591-023-02479-1. Epub 2023 Aug 10.; Ostendorf L, Burns M, Durek P, et al. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2020 Sep 17;383(12):1149-1155. doi:10.1056/NEJMoa2023325.; Katsuyama E, Humbel M, Suarez- Fueyo A, et al. CD38 in SLE CD4 T cells promotes Ca(2+) flux and suppresses interleukin-2 production by enhancing the expression of GM2 on the surface membrane. Nat Commun. 2024 Sep 27;15(1):8304. doi:10.1038/s41467-024-52617-7.; Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of ultiple myeloma. Clin Cancer Res. 2013 Apr 15;19(8):2048-60. doi:10.1158/1078-0432.CCR-12-2422. Epub 2013 Jan 23.; Salazar-Camarena DC, Palafox-Sanchez CA, Cruz A, et al. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients. Sci Rep. 2020 Apr 10;10(1):6236. doi:10.1038/s41598-020-63390-0.; Rodriguez-Carrio J, Alperi-Lopez M, Lopez P, et al. Profiling of B-Cell Factors and Their Decoy Receptors in Rheumatoid Arthritis: Association With Clinical Features and Treatment Outcomes. Front Immunol. 2018 Oct 11:9:2351. doi:10.3389/fimmu.2018.02351. e Collection 2018.; Nagatani K, Itoh K, Nakajima K, et al. Rheumatoid arthritis fibroblast-like synoviocytes express BCMA and are stimulated by APRIL. Arthritis Rheum. 2007 Nov;56(11): 3554-63. doi:10.1002/art.22929.; Verdun N, Marks P. Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2024 Feb 15;390(7): 584-586. doi:10.1056/NEJMp2400209. Epub 2024 Jan 24.; Shah K, Leandro M, Cragg M, et al. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? Clin Exp Immunol 2024; 217(1):15-30. doi:10.1093/cei/uxae031
-
3Academic Journal
Source: Клиническая онкогематология, Vol 15, Iss 4 (2022)
Subject Terms: 0301 basic medicine, 03 medical and health sciences, плазматические клетки, костный мозг, 0302 clinical medicine, минимальная остаточная болезнь, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, множественная миелома, многоцветная проточная цитометрия, RC254-282, 3. Good health
-
4Academic Journal
Source: Клиническая онкогематология, Vol 15, Iss 4 (2022)
Subject Terms: 0301 basic medicine, 03 medical and health sciences, плазматические клетки, 0302 clinical medicine, общая выживаемость, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, множественная миелома, иммунофенотипический профиль, бортезомиб, проточная цитометрия, RC254-282, 3. Good health
-
5Academic Journal
Authors: Gaidar, Yu.А., Arzhanova, G.Yu., Galenko, A.P.
Source: Gastroenterologìa, Vol 51, Iss 2, Pp 111-114 (2017)
GASTROENTEROLOGY; Том 51, № 2 (2017); 111-114
Гастроэнтерология-Gastroenterologìa; Том 51, № 2 (2017); 111-114
Гастроентерологія-Gastroenterologìa; Том 51, № 2 (2017); 111-114Subject Terms: Crohn's disease, 03 medical and health sciences, 0302 clinical medicine, IgG4-позитивные плазматические клетки, неспецифический язвенный колит, болезнь Крона, IgG4-позитивні плазматичні клітини, неспецифічний виразковий коліт, хвороба Крона, IgG4-positive plasma cells, RC799-869, Diseases of the digestive system. Gastroenterology, ulcerative colitis, 3. Good health
File Description: application/pdf
Access URL: http://gastro.zaslavsky.com.ua/article/download/101700/98136
https://doaj.org/article/242f8803e5fc48e1b36bdbcb720f81cb
http://gastro.zaslavsky.com.ua/article/download/101700/98136
https://core.ac.uk/display/87799497
http://gastro.zaslavsky.com.ua/article/view/101700
https://cyberleninka.ru/article/n/state-of-igg4-positive-plasma-cells-in-the-colon-mucosa-of-chronic-inflammatory-bowel-disease
http://gastro.zaslavsky.com.ua/article/view/101700 -
6Academic Journal
Authors: E. S. Kuvardin, I. V. Kholopova, E. A. Belyakova, I. N. Grigoryeva, A. V. Masing, O. Yu. Tkachenko, I. A. Bekhtereva, A. L. Maslyansky, Yu. A. Krivolapov, S. V. Lapin, Е. С. Кувардин, И. В. Холопова, Е. А. Белякова, И. Н. Григорьева, А. В. Мазинг, О. Ю. Ткаченко, И. А. Бехтерева, А. Л. Маслянский, Ю. А. Криволапов, С. В. Лапин
Source: Modern Rheumatology Journal; Том 17, № 1 (2023); 24–30 ; Современная ревматология; Том 17, № 1 (2023); 24–30 ; 2310-158X ; 1996-7012
Subject Terms: плазматические клетки, immunoglobulin free light chains, saliva, plasma cells, свободные легкие цепи иммуноглобулинов, слюна
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1384/1322; Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjцgren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2017 Jan;69(1): 35-45. doi:10.1002/art.39859. Epub 2016 Oct 26.; Qin B, Wang J, Yang Z, et al. Epidemiology of primary Sjцgren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Nov;74(11):1983-9. doi:10.1136/annrheumdis-2014-2053. Epub 2014 Jun 17.; Caporali R, Bonacci E, Epis O, et al. Safety and usefulness of minor salivary gland biopsy: retrospective analysis of 502 procedures performed at a single center. Arthritis Rheum. 2008 May 15;59(5):714-20. doi:10.1002/art.23579.; Thorlacius GE, Hultin-Rosenberg L, Sandling JK, et al. Genetic and clinical basis for two distinct subtypes of primary Sjоgren's syndrome. Rheumatology (Oxford). 2021 Feb 1; 60(2):837-48. doi:10.1093/rheumatology/keaa367.; Carubbi F, Alunno A, Cipriani P, et al. Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjцgren's syndrome minor salivary glands. PLoS One. 2019 Jan 25;14(1):e0211142. doi:10.1371/journal.pone.0211142. eCollection 2019.; Shoenfeld Y, Meroni PL, Gershwin ME. Autoantibodies. Waltham: Elsevier; 2014. P. 233-8.; Brito-Zerуn P, Acar-Denizli N, Zeher M, et al. How does primary Sjögren syndrome present in biopsy-proven patients without circulating rola autoantibodies? Characteristics at diagnosis of 2073 patients from the Sjögren big data project. https://acrabstracts.org/abstract/sjogren-big-data-project-influence-ofgeolocation-on-the-phenotypic-expressionat-diagnosis-in-8310-patients-north-tosouth-gradient/; Aqrawi LA, Galtung HK, Guerreiro EM, et al. Proteomic and histopathological characterisation of sicca subjects and primary Sjögren's syndrome patients reveals promising tear, saliva and extracellular vesicle disease biomarkers. Arthritis Res Ther. 2019 Jul 31; 21(1):181. doi:10.1186/s13075-019-1961-4.; Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. J Autoimmun. 2010 Jun;34(4):400-7. doi:10.1016/j.jaut.2009.10.004. Epub 2009 Nov 3.; Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjögren syndrome. Nat Rev Rheumatol. 2018 Mar;14(3):133-45. doi:10.1038/nrrheum.2018.1. Epub 2018 Feb 8.; Sandhya P, Christudoss P, Kabeerdoss J, et al. Diagnostic accuracy of salivary and serum-free light chain assays in primary Sjögren's syndrome: a pilot study. Int J Rheum Dis. 2017 Jun;20(6):760-766. doi:10.1111/1756-185X.12965. Epub 2016 Dec 30.; Verstappen GM, Moerman RV, van Nimwegen JF, et al. Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren's syndrome. Rheumatology (Oxford). 2018 Oct 1;57(10):1812-21. doi:10.1093/rheumatology/key180.; Navazesh M, Kumar SK. Measuring salivary flow: challenges and opportunities. J Am Dent Assoc. 2008 May;139 Suppl:35S-40S. doi:10.14219/jada.archive.2008.; Тотолян АА. Современные подходы к диагностике иммунопатологических состояний. Медицинская иммунология. 1999;1(1-2):75-108.; Teppo H, Revonta M. A follow-up study of minimally invasive lip biopsy in the diagnosis of Sjögren's syndrome. Clin Rheumatol. 2007 Jul;26(7):1099-103. doi:10.1007/s10067-006-0457-1. Epub 2006 Nov 25.; Katsiougiannis S, Wong DTW. The Proteomics of Saliva in Sjögren's Syndrome. Rheum Dis Clin North Am. 2016;42(3):449-56. doi:10.1016/j.rdc.2016.03.004. Epub 2016 Jun 21.; Szyszko EA, Brokstad KA, Oijordsbakken G, et al. Salivary glands of primary Sjögren's syndrome patients express factors vital for plasma cell survival. Arthritis Res Ther. 2011 Jan 7;13(1):R2. doi:10.1186/ar3220.; Mingueneau M, Boudaoud S, Haskett S, et al. Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol. 2016 Jun;137(6):1809-21.e12. doi:10.1016/j.jaci.2016.01.024. Epub 2016 Apr 1.; Будкова АИ, Лапин СВ, Серебрякова МК и др. Субпопуляционный состав В-клеток периферической крови у больных системной красной волчанкой. Медицинская иммунология. 2017;19(2):175-84.; Hamza N, Bootsma H, Yuvaraj S, et al. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy. Ann Rheum Dis. 2012 Nov;71(11): 1881-7. doi:10.1136/annrheumdis-2011-201189. Epub 2012 May 21.; Takeshita M, Suzuki K, Kaneda Y, et al. Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands. Ann Rheum Dis. 2020 Jan;79(1):150-8. doi:10.1136/annrheumdis-2019-215862. Epub 2019 Oct 14.; Bookman AA, Shen H, Cook RJ, et al. Whole stimulated salivary flow: correlation with the pathology of inflammation and damage in minor salivary gland biopsy specimens from patients with primary Sjögren's syndrome but not patients with sicca. Arthritis Rheum. 2011 Jul;63(7):2014-20. doi:10.1002/art.30295.; Tarn JR, Howard-Tripp N, Lendrem DW, et al. Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol. 2019 Sep 25;1(2):e85-94. doi:10.1016/S2665-9913(19)30042-6.; Sandhya P, Kabeerdoss J, Christudoss P, et al. Salivary free light chains and salivary immunoglobulins as potential non-invasive biomarkers in primary Sjögren's syndrome. Int J Rheum Dis. 2022;25(1):61-9. doi:10.1111/1756-185X.14242. Epub 2021 Nov 17.; Fox PC, Datiles M, Atkinson JC, et al. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol. 1993 Mar-Apr;11(2):149-56.
-
7Academic Journal
Authors: E. V. Batorov, T. A. Aristova, N. V. Pronkina, V. V. Denisova, S. A. Sizikova, G. Yu. Ushakova, Е. В. Баторов, Т. А. Аристова, Н. В. Пронкина, В. В. Денисова, С. А. Сизикова, Г. Ю. Ушакова
Contributors: This work is supported by the Russian Science Foundation under grant No. 20-75-10132.
Source: Medical Immunology (Russia); Том 25, № 5 (2023); 1151-1158 ; Медицинская иммунология; Том 25, № 5 (2023); 1151-1158 ; 2313-741X ; 1563-0625
Subject Terms: множественная миелома, PD-1, TIM-3, T cells, tumor plasma cells, multiple myeloma, Т-лимфоциты, опухолевые плазматические клетки
File Description: application/pdf
Relation: https://www.mimmun.ru/mimmun/article/view/2760/1763; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2760/11455; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2760/11456; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2760/11457; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2760/11458; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2760/11459; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2760/11460; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2760/11461; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2760/12111; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2760/12120; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2760/12125; Atanackovic D., Luetkens T., Radhakrishnan S., Kroger N. Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of multiple myeloma. Curr. Cancer Drug Targets, 2017, Vol. 17, no. 9, pp. 839-845.; Batorov E.V., Aristova T.A., Sergeevicheva V.V., Sizikova S.A., Ushakova G.Y., Pronkina N.V., Shishkova I.V., Shevela E.Y., Ostanin A.A., Chernykh E.R. Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients. Sci. Rep., 2020, Vol. 10, 20846. doi:10.1038/s41598-020-77941-y.; Chang Y., Jiang Y., Chen Y., Xing X., Zhou Y., Sang T., Li J., Zhao A., Zhang J., Zhao J., Liu Y., Zheng C. Bone marrow PD-1 positive T cells reflect tumor mass and prognosis in multiple myeloma. Int. J. Clin. Exp. Pathol., 2018, Vol. 11, no. 1, pp. 304-313.; Christiansson L., Soderlund S., Svensson E., Mustjoki S., Bengtsson M., Simonsson B., Olsson-Stromberg U., Loskog A.S.I. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS One, 2013, Vol. 8, e55818. doi:10.1371/journal.pone.0055818.; de Veirman K., van Valckenborgh E., Lahmar Q., Geeraerts X., de Bruyne E., Menu E., van Riet I., Vanderkerken K., van Ginderachter J.A. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front. Oncol., 2014, Vol. 4, 349. doi:10.3389/fonc.2014.00349.; Gabrilovich D.I. Myeloid-derived suppressor cells. Cancer Immunol. Res., 2017, Vol. 5, no. 1, pp. 3-8.; Gorgun G., Samur M.K., Cowens K.B., Paula S., Bianchi G., Anderson J.E., White R.E., Singh A., Ohguchi H., Suzuki R., Kikuchi S., Harada T., Hideshima T., Tai Y.-T., Laubach J.P., Raje N., Magrangeas F., Minvielle S., Avet- Loiseau H., Munshi N.C., Dorfman D.M., Richardson P.G., Anderson K.C. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin. Cancer Res., 2015, Vol. 21, no. 20, pp. 4607-4618.; Haile L.A., Greten T.F., Korangy F. Immune suppression: the hallmark of myeloid derived suppressor cells. Immunol. Invest., 2012, Vol. 41, no. 6-7, pp. 581-594.; Hou A., Hou K., Huang Q., Lei Y., Chen W. Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors. Front. Immunol., 2020, Vol. 11, 783. doi:10.3389/fimmu.2020.00783.; Malek E., de Lima M., Letterio J.J., Kim B.G., Finke J.H., Driscoll J.J., Giralt S.A. Myeloid-derived suppressor cells: The green light for myeloma immune escape. Blood Rev., 2016, Vol. 30, no. 5, pp 341-348.; Marini O., Spina C., Mimiola E., Cassaro A., Malerba G., Todeschini G., Perbellini O., Scupoli M., Carli G., Facchinelli D., Cassatella M., Scapini P., Tecchio C. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. Oncotarget, 2016, Vol. 7, no. 19, pp. 27676-27688.; Sponaas A.-M., Yang R., Rustad E.H., Standal T., 'Ihoresen A.S., Dao Vo C., Waage A., Skrdahl T.S., B0rset M., Sundan A. PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients. Oncotarget, 2018, Vol 9, no. 62, pp 32024-32035.; Tan J., Chen S., Huang J., Chen Y., Yang L., Wang C., Zhong J., Lu Y., Wang L., Zhu K., Li Y. Increased exhausted CD8+ T cells with programmed death-1, T-cell immunoglobulin and mucin-domain- containing-3 phenotype in patients with multiple myeloma. Asia. Pac. J. Clin. Oncol., 2018, Vol. 14, no. 5, pp. e266-e274.; Wherry E., Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol., 2015, Vol. 15, pp. 486-499.; Yazdani Y., Mohammadnia-Afrouzi M., Yousefi M., Anvari E., Ghalamfarsa G., Hasannia H., Sadreddini S., Jadidi-Niaragh F. Myeloid-derived suppressor cells in B cell malignancies. Tumour Biol., 2015, Vol. 36, no. 10, pp. 7339-7353.; https://www.mimmun.ru/mimmun/article/view/2760
-
8Academic Journal
Authors: Н.А.Орипова
Subject Terms: Ключевые слова: Эпителиальные клетки, внутриэпителиальные лимфоциты (ВЭЛ), Т- и В-лимфоциты, плазматические клетки, пейеровы бляшки
Relation: https://zenodo.org/records/6227283; oai:zenodo.org:6227283; https://doi.org/10.5281/zenodo.6227283
-
9Academic Journal
Authors: E. S. Kuvardin, I. N. Grigor’yeva, I. A. Bekhtereva, A. L. Maslyansky, Yu. A. Krivolapov, E. A. Belyakova, Е. С. Кувардин, И. Н. Григорьева, И. А. Бехтерева, А. Л. Маслянский, Ю. А. Криволапов, Е. А. Белякова
Source: Rheumatology Science and Practice; Vol 59, No 4 (2021); 434–441 ; Научно-практическая ревматология; Vol 59, No 4 (2021); 434–441 ; 1995-4492 ; 1995-4484
Subject Terms: плазматические клетки, biopsy, immunohistochemistry, small salivary gland, T cells, B cells, macrophages, follicular dendritic cells, plasmacytes, биопсия, иммуногистохимическое исследование, малая слюнная железа, Т-клетки, В-клетки, макрофаги, фолликулярные дендритные клетки
File Description: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3061/2113; Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2017:464.; Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sjögren’s syndrome: A systematic review and meta-analysis. Ann Rheum Dis. 2015;74:1983-1989. doi:10.1136/annrheumdis-2014-205375; Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/ European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69:35-45. doi:10.1002/art.39859; Guellec D, Cornec D, Jousse-Joulin S, Marhadour T, Marcorelles P, Pers JO, et al. Diagnostic value of labial minor salivary gland biopsy for Sjögren’s syndrome: A systematic review. Autoimmun Rev. 2013;12:416-420. doi:10.1016/j.autrev.2012.08.001; Bodeutsch C, de Wilde PC, Kater L, van Houwelingen JC, van den Hoogen FH, Kruize AA, et al. Quantitative immunohistologic criteria are superior to the lymphocytic focus score criterion for the diagnosis of Sjögren’s syndrome. Arthritis Rheum. 1992;35:1075-1087. doi:10.1002/art.1780350913; van Woerkom JM, Kruize AA, Barendregt PJ, Kater L, Hené R, Bootsma H, et al. Clinical significance of quantitative immunohistology in labial salivary glands for diagnosing Sjogren’s syndrome. Rheumatology (Oxford). 2006;45:470-477. doi:10.1093/rheumatology/kei191; Fisher BA, Jonsson R, Daniels T, Bombardieri M, Brown RM, Morgan P, et al. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjogren’s syndrome. Ann Rheum Dis. 2017;76:1161-1168. doi:10.1136/annrheumdis-2016-210448; Navazesh M, Kumar SKS. Measuring salivary flow. Dent Assist J. 2008;139:35S-40S. doi:10.14219/jada.archive.2008.0353; Teppo H, Revonta M. A follow-up study of minimally invasive lip biopsy in the diagnosis of Sjögren’s syndrome. Clin Rheumatol. 2007;26:1099-1103. doi:10.1007/s10067-006-0457-1; Quartuccio L, Baldini C, Bartoloni E, Priori R, Carubbi F, Corazza L, et al. Anti-SSA/SSB-negative Sjögren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev. 2015;14:1019-1022. doi:10.1016/j.autrev.2015.07.002; Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun. 2010;34:400–407. doi:10.1016/j.jaut.2009.10.004; Jonsson MV, Skarstein K. Follicular dendritic cells confirm lymphoid organization in the minor salivary glands of primary Sjögren’s syndrome. J Oral Pathol Med. 2008;37:515-521. doi:10.1111/j.1600-0714.2008.00674.x; Braun M, Melchers I, Peter HH, Illges H. Human B and T lymphocytes have similar amounts of CD21 mRNA, but differ in surface expression of the CD21 glycoprotein. Int Immunol. 1998;10(8):1197-1202.; Daridon C, Pers JO, Devauchelle V, Martins-Carvalho C, Hutin P, Pennec YL, et al. Identification of transitional type II B cells in the salivary glands of patients with Sjögren’s syndrome. Arthritis Rheum. 2006;54:2280-2288. doi:10.1002/art.21936; Le Pottier L, Devauchelle V, Fautrel A, Daridon C, Saraux A, Youinou P, et al. Ectopic germinal centers are rare in Sjogren’s syndrome salivary glands and do not exclude autoreactive B cells. J Immunol. 2009;182:3540-3547. doi:10.4049/jimmunol.0803588; Ushio A, Arakaki R, Yamada A, Saito M, Tsunematsu T, Kudo Y, et al. Crucial roles of macrophages in the pathogenesis of autoimmune disease. World J Immunol. 2017;7(1):1-8. doi:10.5411/wji.v7.i1.1; Ushio A, Arakaki R, Otsuka K, Yamada A, Tsunematsu T, Kudo Y, et al. CCL22-producing resident macrophages enhance T cell response in Sjögren’s syndrome. Front Immunol. 2018;9:2594. doi:10.3389/fimmu.2018.02594
-
10Academic Journal
Authors: V. N. Ellinidi, N. N. Khromov-Borisov, A. A. Feoktistov, A. V. Lyamina, N. M. Kalinina, В. Н. Эллиниди, Н. Н. Хромов-Борисов, А. А. Феоктистов, А. В. Лямина, Н. М. Калинина
Source: Medical Immunology (Russia); Том 21, № 3 (2019); 451-456 ; Медицинская иммунология; Том 21, № 3 (2019); 451-456 ; 2313-741X ; 1563-0625 ; 10.15789/1563-0625-2019-3
Subject Terms: иммуногистохимическое исследование, plasma cells, CD138, CD20, B lymphocytes, immunohistochemical assay, плазматические клетки, В-лимфоциты
File Description: application/pdf
Relation: https://www.mimmun.ru/mimmun/article/view/1818/1142; ГОСТ Р 53022.3-2008. Технологии лабораторные клинические. Требования к качеству клинических лабораторных исследований. Часть 3. Правила оценки клинической информативности лабораторных тестов. М.: Стандартинформ, 2009. 20 с.; Хмельницкий О.К. Патоморфологическая диагностика гинекологических заболеваний. СПб.: СОТИС-Мед, 1994. 480 с.; Bayer-Garner I.B., Korourian S. Plasma cell in chronic endometritis are easily identified when stained with Syndecan-1. Mod. Pathol., 2001, Vol. 14, pp. 877-879.; Benjamin D.J., Berger J., Johannesson M., Nosek B.A., Wagenmakers E.J., Berk R., Bollen K., et al. Redefine Statistical Significance. PsyArXiv, 2017.; Bouet P.E., el Hachem H., Monceau E., Gariépy G., Kadoch I.J., Sylvestre C. Chronic endometritis in women with recurrent pregnancy loss and recurrent implantation failure: prevalence and role of office hysteroscopy and immunohistochemistry in diagnosis. Fertil. Steril., 2016, Vol. 105, pp. 106-110.; Calame K.L., Lin K.-I., Tunyapline C. Regulatory mechanism that determine the development and function of plasma cells. Ann. Rev. Immunol., 2003, Vol. 21, pp. 205-209.; Crum C.P., Egawa K., Fenoglio C.M., Richart R.M. Chronic endometritis: The role of immunohistochemistry in the detection of plasma cells. Am. J. Obstet. Gynecol., 1983, Vol. 147, pp. 812-815.; Greenwood S.M., Moran J.J. Chronic endometritis morphologic and clinical observations. Obstet. Gynecol., 1981, Vol. 58, pp. 176-184.; Kasius J.C., Fatemi H.M., Bourgain C., Sie-Go D.M., Eijkemans R.J., Fauser B.C., Devroey P., Broekmans F.J. The impact of chronic endometritis on reproductive outcome. Fertil. Steril., 2011, Vol. 96, pp. 1451-1456.; Kitaya K.1., Yasuo T. Immunohistochemistrical andclinicopathological characterization of chronic endometritis. Am J. Reprod. Immunol., 2011, Vol. 66, pp. 410-415.; Xia J., Wishart D.S. Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis. Curr. Protoc. Bioinformatics, 2016, Vol. 55, 14.10.1-14.10.91. doi:10.1002/cpbi.11.; https://www.mimmun.ru/mimmun/article/view/1818
-
11Academic Journal
Source: Клиническая онкогематология, Vol 6, Iss 3 (2013)
-
12Academic Journal
Authors: I. N. Chernyshova, M. V. Gavrilova, L. V. Komarova, E. V. Sidorova, И. Н. Чернышова, М. В. Гаврилова, Л. В. Комарова, Е. В. Сидорова
Source: Medical Immunology (Russia); Том 17, № 2 (2015); 127-134 ; Медицинская иммунология; Том 17, № 2 (2015); 127-134 ; 2313-741X ; 1563-0625 ; 10.15789/1563-0625-2015-2
Subject Terms: антитело-продуценты, alpha (1→3) dextran, bone marrow, CD138+ plasma cells, long-lived plasmocytes, antibody-producing cells, альфа (1→3) декстран, костный мозг, CD138+ плазматические клетки, долгоживущие плазматические клетки
File Description: application/pdf
Relation: https://www.mimmun.ru/mimmun/article/view/830/762; Сидорова Е.В. Долгоживущие В-клетки // Успехи современной биологии, 2013. Т. 133, No 4. С.333-348. [Sidorova E.V. Long-lived B cells. Uspekhi sovremennoy biologii = Biology Bulletin Reviews, 2013, Vol. 133, no. 4, pp. 333-348. (In Russ.)]; Хоченков Дм.А. Роль дендритных клеток в иммунном ответе на Т-независимые антигены типа 2 // Биологические мембраны, 2010. Т. 27, No 4. С.307-313. [Khochenkov D.A. Role of dendritic cells in the immune response to T-independent antigens type 2. Biologicheskie membrany = Biochemistry (Moscow) Supplement Series A, 2010, Vol. 27. no. 4, pp. 307-313. (In Russ.)]; Choi Y.S., Dieter J.A., Rothaeusler K., Luo Z., Baumgarth N. B-1 cells in the bone marrow are a significant source of natural IgM. Eur. J. Immunol., 2012, Vol. 42, no. 1, pp. 120-129.; Foote J.B., Mahmoud T.I., Vale A.M., Kearney J.F. Long-term maitenance of polysaccharide-specific antibodies by IgM-secreting cells. J. Immunol., 2012, Vol. 188, no. 1, pp. 57-67.; Manz R.A., Löhning M., Cassese G., Thiel A., Radbruch A. Survival of long-lived plasma cells is independent of antigen. Int. Immunol., 1998, Vol. 10, no. 11, pp. 1703-1711.; Heather A., Minges Wols, Pamela L. Witte. Plasma cell purification from murine bone marrow using a twostep isolation approach. J. Immunol. Meth., 2008, Vol. 329, no. 1-2, pp. 219-224.; Kopper L, Sebestyen A, Gallai M, Kovalszky I. Syndecan-1 – a new piece in B-cell Puzzle. Pathology Oncology Research, 1997, Vol. 3, no. 3, pp. 183-191.; Racine R., McLaughlin M., Jones D.D., Wittmer S.T., MacNamara K.C., Woodland D.L., Winslow G.M. IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection. J. Immunol., 2011, Vol. 186, no. 2, pp. 1011-1021.; Slifka M.K., Antia R., Whitmire J.K., Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity, 1998, Vol. 8, no. 3, pp. 363-372.; Slifka M.K., Matloubian M., Ahmed R. Bone marrow is a major site of long-term antibody production after acute viral infection. J. Virol., 1995, Vol. 69, no. 3, pp. 1895-1902.; Taillardet M., Haffar G., Mondière P., Asensio M.J., Gheit H., Burdin N., Defrance T., Genestier L. The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells. Blood, 2009, Vol. 114, no. 20, pp. 4432-4440.; Tung J.W., Mrazek M.D., Yang Y., Herzenberg L.A., Herzenberg L.A. Phenotypically distinct B cell development pathways map to the three B cell lineages in the mouse. Proc. Natl. Acad. Sci USA, 2006, Vol. 103, no. 16, pp. 6293-6298.; https://www.mimmun.ru/mimmun/article/view/830
-
13Academic Journal
Authors: Andreychyn, Yu. M., Kovalenko, I. S.
Source: Pathologia; Vol. 14 No. 1 (2017): Pathologia ; Патология; Том 14 № 1 (2017): Патологія ; Патологія; Том 14 № 1 (2017): Патологія ; 2310-1237 ; 2306-8027
Subject Terms: maxillary sinusitis, adenomatous polyp, subpopulation of T-lymphocytes, macrophages, plasma cells, верхнечелюстной синусит, аденоматозный полип, субпопуляции Т-лимфоцитов, макрофаги, плазматические клетки, верхньощелепний синусит, аденоматозний поліп, субпопуляції Т-лімфоцитів, плазматичні клітини
Relation: http://pat.zsmu.edu.ua/article/view/97793/95722; http://pat.zsmu.edu.ua/article/view/97793
Availability: http://pat.zsmu.edu.ua/article/view/97793
-
14Academic Journal
Authors: Karamysheva A.F.
Source: Advances in Molecular Oncology; Vol 2, No 3 (2015); 43-50 ; Успехи молекулярной онкологии; Vol 2, No 3 (2015); 43-50 ; 2413-3787 ; 2313-805X
Subject Terms: multiple myeloma, plasma cells, multiple myeloma markers, CD138, syndecan-1, vascular endothelial growth factor receptor, VEGFR3, plasma cell populations, prognosis, множественная миелома, плазматические клетки, маркеры множественной миеломы, синдекан-1, рецептор фактора роста эндотелия сосудов VEGFR3, популяции плазмоцитов, прогноз
File Description: application/pdf
Relation: https://umo.abvpress.ru/jour/article/view/44/46; https://umo.abvpress.ru/jour/article/view/44
-
15Academic Journal
Authors: СУПОНИЦКАЯ ЕКАТЕРИНА ВАЛЕРЬЕВНА, АЛЕКСАНКИН А.П., АЛЕКСАНДРОВА Е.Н., АВДЕЕВА А.С., ПАНАФИДИНА Т.А., ВЕРИЖНИКОВА Ж.Г., НАСОНОВ Е.Л.
Subject Terms: ПРОТОЧНАЯ ЦИТОФЛУОРОМЕТРИЯ, CD19+В-КЛЕТКИ, В-КЛЕТКИ ПАМЯТИ, НАИВНЫЕ В-КЛЕТКИ, ТРАНЗИТОРНЫЕ В-КЛЕТКИ, ПЛАЗМОБЛАСТЫ, ДОЛГОЖИВУЩИЕ ПЛАЗМАТИЧЕСКИЕ КЛЕТКИ, РЕВМАТОИДНЫЙ АРТРИТ, СИСТЕМНАЯ КРАСНАЯ ВОЛЧАНКА, CD19+CELLS
File Description: text/html
-
16Academic Journal
Authors: ГРИГОРЕНКО Д.Е.
Subject Terms: ЛИМФОИДНАЯ ТКАНЬ, КЛЕТОЧНЫЙ СОСТАВ, ЛИМФОЦИТЫ, ПЛАЗМАТИЧЕСКИЕ КЛЕТКИ
File Description: text/html
-
17Academic Journal
Authors: КАРАМЫШЕВА А.Ф.
File Description: text/html
-
18Academic Journal
Authors: БАРАТОВА М.А., БАРАТОВА Д.А.
Subject Terms: БОЛЬНЫЕ КИРГИЗСКОЙ НАЦИОНАЛЬНОСТИ, ПЛАЗМАТИЧЕСКИЕ КЛЕТКИ, ПАРАПРОТЕИН, АНЕМИЯ, МНОЖЕСТВЕННАЯ МИЕЛОМА
File Description: text/html
-
19Academic Journal
Authors: Герке, А.
Subject Terms: ПЛАЗМАТИЧЕСКИЕ КЛЕТКИ, ПОДОДЕРМАТИТ, КОШКА
File Description: text/html
-
20Academic Journal
Authors: ГРИГОРЕНКО Д.Е., АМИНОВА Г.Г.
Subject Terms: ЖЕЛУДОК, ЛИМФОИДНАЯ ТКАНЬ, ПЛАЗМАТИЧЕСКИЕ КЛЕТКИ, ЛИМФОЦИТЫ, ДЕСТРУКЦИЯ
File Description: text/html
